Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

Summary

Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by * % change in forced vital capacity (FVC) * % fibrosis in high resolution computed tomography (HRCT) of the lung

Timeline

Start

2020-08-01

Primary completion

2022-01-30

Completion

2022-06-30

Drugs

Indications